From the Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710
Received for publication, February 28, 2001, and in revised form, March 26, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Necrotic cell death yields the release of
cellular components that can function in the initiation of cellular
immune responses. Given the established capacity of the endoplasmic
reticulum chaperone GRP94 (gp96) to elicit CD8+ T
cell activation, we have investigated the cellular fate and antigenicity of GRP94 in differing scenarios of cell death. Virally induced cell death or mechanical cell death, elicited by freeze/thaw treatment of cell suspensions, yielded GRP94 release into the extracellular space; apoptotic cell death occurring in response to
serum deprivation did not elicit GRP94 release. To assess the antigenicity of GRP94 released following virally induced cell death
(lethal infection of cells with rVV
ES-OVAMet258-265, a recombinant, ovalbumin
epitope-expressing vaccinia virus) or mechanical cell death
(freeze/thaw of ovalbumin-expressing cells), tissue culture supernatant
fractions were pulsed onto antigen-presenting cells, and antigen
re-presentation was assayed as activation of an ovalbumin-specific T
cell hybridoma. For both cell death scenarios, released GRP94 elicited
a dose-dependent, ovalbumin-specific, hybridoma activation.
In contrast, calreticulin derived from rVV ES-OVAMet258-265-infected cell extracts did not stimulate B3Z activity. These data identify GRP94 as an antigenic component released upon pathological, but not apoptotic, cell death and provide
an assay system for the identification of cellular components of
related activity.
The endoplasmic reticulum molecular chaperone GRP94 (gp96)
can elicit both prophylactic and therapeutic CD8+ cytotoxic
T lymphocyte responses against host tissue-derived antigens (1-5). As
a chaperone, GRP94 interacts with nascent (poly)peptides undergoing
structural maturation in the endoplasmic reticulum
(ER),1 the site of peptide
loading onto nascent major histocompatibility (MHC) class I molecules
(6, 7). This (poly)peptide binding activity, viewed with respect to the
subcellular localization of GRP94, provides insight into the derivation
of GRP94 immunogenicity; it resides in the recipient compartment for
peptides transported by the transporter associated with antigen
presentation (TAP) (7). Furthermore, antigen-presenting cells (APCs)
can internalize GRP94-peptide complexes from the extracellular space by
both receptor-mediated and bulk flow mechanisms (8-10). Recent
evidence indicates that GRP94-peptide complexes internalized via the
receptor-mediated pathway gain access to the MHC class I antigen
presentation pathway, yielding re-presentation of GRP94-associated
peptides on APC MHC class I molecules, an example of a process referred
to as cross-priming or cross-presentation (8, 10, 11).
Although it is clear that GRP94-peptide complexes can elicit cytotoxic
T lymphocyte responses, a finding of substantial therapeutic implications, it is not known whether GRP94 can function in a physiological context to regulate cellular immune responses. The physiological setting of greatest relevance to chaperone-elicited immune responses is that of cell death (broadly speaking,
necrosis and apoptosis). Although a precise terminology for
unambiguously distinguishing necrosis and apoptosis continues to
evolve, the principal physiological difference between the two forms of
cell death is that apoptosis is an essential physiological mechanism in
growth, differentiation, and tissue remodeling, whereas necrosis is a
pathological end point (12, 13). Importantly, necrotic cell death
results in inflammation and stimulation of the host immune system
(14-16). The contribution of the inflammatory response to the
regulation of cellular immune responses is a central element of the
"danger hypothesis," which predicts that the immune system of the
host responds to antigens in the context of a physiological danger
signal (15). In this view, the initiation of a cellular immune response
requires both the antigen and inflammation-induced co-stimulatory
factors that stimulate APC cell maturation and antigen presentation.
Indeed, recent work indicates that necrotic cells and their
supernatants can induce maturation of dendritic cells, as well as
provide antigens for re-presentation to CD8+ T cells
(16-19). At present, the full identity of the necrotic cell components
that elicit APC activation and serve as the source of antigenic
component(s) necessary for the elicitation and maintenance of a
cellular immune response remains to be determined (19, 20).
In this study, we report that lethal viral infection and mechanical
cell death elicited the release of GRP94 into the extracellular medium,
whereas apoptotic cell death did not. GRP94 released as a consequence
of viral infection was structurally intact, it could be internalized by
APCs, and its bound peptides re-presented for T cell activation.
These data extend recent findings that necrotic cell extracts stimulate
APC maturation and re-presentation and establish GRP94 as a candidate
physiological mediator of necrosis-dependent immune
responses (16, 18, 19).
Cells--
EL4 and E.G7-OVA are murine thymomas, E.G7-OVA being
EL4 cells stably transfected with the gene encoding chicken ovalbumin (21). B3Z is a CD8+ T cell hybridoma that expresses
LacZ in response to activation of T cell receptors specific for
the SIINFEKL peptide (OVA-immunodominant peptide) in the context of
H-2Kb MHC class I molecules (22). P815 is a murine
mastocytoma cell line, H-2d haplotype, expressing the P1A
tumor antigen. RAW309 Cr.1, a Kd/Kb
murine macrophage cell line, was obtained from ATCC (ATCC
TIB-69). All cells were cultured in Dulbecco's modified Eagle's
medium, 10% fetal calf serum.
Cell Death-dependent Release of Heat Shock
Proteins--
To analyze GRP94 release following mechanical
(nonphysiological) cell death, cultures of E.G7-OVA cells were killed
by freeze/thaw treatment (16, 18), the addition of digitonin to
0.005%, or the addition of 5 µM ionomycin. For the
latter two conditions the cells were incubated as such for 6 h at
37 °C. In experiments addressing mechanical cell death, 1 × 106 cells were used in the preparation of cell extracts.
Following the indicated treatment, cell suspensions were centrifuged
(15 min, 50,000 rpm, Beckman TL100.2 rotor), and the resulting
supernatant was retained as the soluble fraction. Tissue culture
supernatant extracts were subjected to ammonium sulfate fractionation
(40% w/v), and the glycoprotein fraction remaining in the 40%
ammonium sulfate supernatant was purified by adsorption onto
concanavalin A-Sepharose beads (Amersham Pharmacia Biotech). Bound
glycoproteins were eluted from the concanavalin A beads with SDS-PAGE
sample buffer (0.5 M Tris, 5% SDS) and analyzed by
immunoblot for GRP94 content. The anti-GRP94 antibody (DU120) was
prepared by contract service with Cocalico Biologicals (Reamstown, PA).
For the induction of pathological cell death, P815 cells were infected
with rVV ES-OVAMet258-265, a recombinant vaccinia virus
encoding the modified ovalbumin epitope MIINFEKL in a signal sequence-bearing minigene construct (23), at a multiplicity of
infection of 5 for 1 h in balanced salt solution, 0.1% bovine serum albumin (BSS/BSA). BSS/BSA medium was then exchanged into Dulbecco's modified Eagle's medium, 10% fetal calf serum, and the
cultures were maintained for 48 h at 37 °C. 48 h
postinfection, cell cultures were centrifuged as above, and the
supernatant fraction was recovered. The ER chaperone content of the
cell pellet was released by sequential extraction of the cell pellet
with 0.05% digitonin and 10 mM CHAPS detergents. The
supernatant fraction was subjected to ultracentrifugation (Beckman
TLA100 rotor, 60,000 rpm, 20 min) prior to fractionation. For the
supernatant fractions, fractionation was performed by gel filtration
chromatography on a Sephacryl S-300 column, with elution performed in
phosphate-buffered saline. Cell pellet detergent extracts were
initially fractionated by MonoQ anion exchange chromatography and
subsequently by gel filtration chromatography, as previously described
(24).
Apoptotic cell death was elicited by transferring EL4 cell cultures
into serum-free Dulbecco's modified Eagle's medium. Following transfer, aliquots of the cell suspension were removed at the indicated
time points for analysis of GRP94 release in the medium (as above),
cell death, as assayed by vital dye (trypan blue) staining, and
apoptotic state, as assayed by fluorescein isothiocyanate-annexin V
staining (Pharmingen) (according to the manufacturer's protocol). For
fluorescein isothiocyanate-annexin V staining, cells were postfixed in
2% paraformaldehyde and assayed by fluorescence-activated cell
sorter analysis.
OVA Re-presentation Assays--
OVA-specific immunogenicity was
determined in a re-presentation assay using the
Kb/Kd macrophage cell line RAW309 and the
OVA-specific T cell hybridoma B3Z. Typically, fractions derived from
the different tissue culture supernatants were added to cultures of
5 × 105 RAW309 cells and 106 B3Z cells,
in a total of 1 ml, as described previously (22). OVA re-presentation
was assayed by the measurement of LacZ activity using
o-nitrophenyl
In experiments involving fractions prepared from E.G7-OVA cells,
contaminating full-length ovalbumin or ovalbumin peptide fragments were
separated from the GRP94 fraction by ultrafiltration on Microcon100
centrifugal ultrafiltration units (Millipore). Processing in the
Microcon100 units yielded efficient fractionation of the supernatant
fractions into low molecular mass (<100 kDa; filtrate) and high
molecular mass (>100 kDa; retentate) fractions. The
GRP94-enriched retentate was collected and either used directly or
depleted of GRP94 by chromatography on an anti-GRP94 immunoaffinity support. The immunoaffinity matrix was prepared using affinity-purified DU120 IgG cross-linked to protein G beads (Sigma). To deplete fractions
of GRP94, aliquots were incubated at a ratio of 3:1 (extract
volume:bead volume) for 90 min at 4 °C with end-over-end mixing.
Subsequently, samples were centrifuged, and the supernatant fraction
was recovered.
Release of Antigenic GRP94 following Cell Death--
Necrotic cell
extracts can stimulate APC activation, maturation, and (coordinately)
antigen re-presentation (16-19, 26). Although the identity of
all necrotic cell-derived components that contribute to the APC
activation response remains to be determined, heat shock and chaperone
proteins have been demonstrated to elicit APC activation and to
serve as cross-presentation antigens in the MHC class I antigen
presentation pathway and thus can be considered candidate molecular
signals of necrotic cell death (5, 15, 17, 19, 20). Here we examined
whether GRP94 (gp96), the endoplasmic reticulum Hsp90, was released
from cells in response to cell death elicited by mechanical, apoptotic,
or pathological cell death and whether the released GRP94 was
immunogenic. Two experimental systems were used. To examine the fate of
GRP94 in mechanical/chemical and apoptotic cell death, E.G7-OVA and EL4 cells were used. Previously, we reported that E.G7-OVA-derived GRP94 is
immunogenic and can elicit OVA (SIINFEKL)-specific CD8+ T
cell responses in vivo (3). To examine the fate of GRP94 upon pathological cell death, P815 mastocytoma cells were infected with
a recombinant vaccinia virus expressing an OVA-peptide minigene (23).
In this system, viral infection yields the trafficking of OVA peptide
to the ER, where it is available for loading onto nascent class I
molecules and, presumably, the endogenous GRP94.
A number of experimental methods for eliciting mechanical/chemical cell
death were used, all of which yielded the hallmark phenotype of either
a rapid disruption in plasma membrane integrity or a profound increase
in plasma membrane ion permeability. Thus, cells were subjected to
multiple freeze/thaw cycles (16, 18, 19), treated with concentrations
of digitonin sufficient to induce selective permeabilization of the
plasma membrane, or subjected to pronounced increases in intracellular
calcium levels by addition of ionomycin (27). After the indicated time
period, cell suspensions were centrifuged, and the soluble fraction was
assayed for the presence of GRP94. As demonstrated in Fig.
1, no GRP94 was seen in tissue culture
supernatants derived from healthy cell cultures (Fig. 1, lane
2), whereas freeze/thaw, ionomycin, and digitonin treatment
yielded the release of GPR94 into the tissue culture supernatant (Fig.
1, lanes 3-5). As depicted in Fig. 1, lanes 6 and 7, lethal viral infection elicited the release of GRP94 into the medium. These findings confirm recent data identifying the
release of GPR94 (gp96) into the soluble fraction following freeze/thaw-elicited cell death and identify a physiological scenario for GRP94 release occurring in response to cell death (19). Under all
conditions examined, the ER membrane proteins remained in association
with the cell pellet (data not shown).
Immunogenicity of Soluble GRP94: Mechanical/Chemical Cell
Death--
Following identification of GRP94 in the supernatant
fraction of killed cell cultures, a series of experiments were
performed to assess the immunogenicity of these GRP94 fractions. For
experiments with GRP94 derived from cells killed through freeze/thaw
treatment, E.G7-OVA cells were used. E.G7-OVA expresses ovalbumin (43 kDa), itself an immunogenic protein in the described re-presentation assay, and so the necrotic cell extracts were first fractionated by
centrifugal ultrafiltration to separate ovalbumin and/or ovalbumin fragments from GRP94 (185 kDa, native molecular mass). As shown in Fig. 2A, two cycles of
ultrafiltration were observed to effectively fractionate GRP94 from
ovalbumin. The specificity of the ultrafiltration-based fractionation
is further depicted in Fig. 2B, where it is shown that
following two cycles of ultrafiltration of the freeze/thaw-treated soluble fraction, GRP94 is recovered wholly in the retentate fraction. It should be noted that GRP94 recovered from freeze/thaw-derived cell
lysates and the tissue culture supernatants of vaccinia-infected cultures was structurally intact. In contrast, apoptotic cell death
has been reported to induce GRP94 proteolysis (28).
To determine whether the GRP94 derived from the freeze/thaw-derived
cell lysates was immunologically active, the GRP94-enriched ultrafiltration retentate fraction, the identical fraction depleted of
GRP94 by adsorption onto affinity-purified monospecific anti-GRP94 IgG,
and medium ± 100 nM ovalbumin were incubated with
RAW309 Cr.1 macrophages, and OVA re-presentation was assayed as
activation of the OVA/Kb-specific T cell hybridoma, B3Z
(22). The linearity of the assay response, using OVA peptide as
standard, is depicted in Fig. 2C. Under the described
conditions, the assay was linear up to 1 absorbance unit. As
depicted in Fig. 2D, the GRP94-enriched, ovalbumin-depleted retentate fraction stimulated the re-presentation assay ~50-fold over
the GRP94-depleted supernatant. This level of activation approximated
that observed upon addition of 100 nM ovalbumin. Immunoaffinity depletion of GRP94 from the retentate fraction reduced
re-presentation to nearly background levels, defined as RAW309 and B3Z
cells cultured in the presence of normal culture medium. These data
indicate that GRP94 contains nearly the entirety of the high molecular
weight OVA-specific immunogenic activity present in a
freeze/thaw-derived cell extract.
Apoptosis Does Not Elicit GRP94 Release--
In contrast to
pathological cell death, apoptotic cell death is a tightly regulated
process (27, 29). Furthermore, endogenous signals derived from necrotic
cells stimulate APC activation and maturation, whereas those from
apoptotic cells do not (16, 18, 19). To assess the effects of apoptotic
cell death on GRP94 release, EL4 cells were serum-deprived, and over a
21-h time course, aliquots of cell-free tissue culture supernatant were
assayed for GRP94 content (Fig.
3A). In paired analyses,
aliquots of the cell fraction were assayed for cell death (trypan blue,
vital dye staining) (Fig. 3B) and apoptosis (annexin V
binding) (Fig. 3C). These data indicate that GRP94 release
into the medium occurred coincident with secondary necrotic cell death
but not with the onset of apoptosis.
Identification of GRP94 as a Primary Immunogenic Component of
Necrotic Cells--
To assess the immunogenic activity of GRP94 in
cells undergoing pathological cell death, the cell-associated GRP94
fraction obtained following lethal infection of P815 mastocytoma cells with a recombinant, OVA-expressing vaccinia virus was examined. To
obtain this fraction, the cell pellet from an rVV
ES-OVAMet258-265 terminal infection was extracted with 10 mM CHAPS detergent, and the resulting soluble protein pool
was fractionated by MonoQ anion exchange chromatography. Fractions from
the MonoQ anion exchange step were assayed for OVA-specific B3Z
activation, and the peak activity fractions were pooled. The pooled
activity peak was then further fractionated by gel filtration
chromatography (Fig. 4). Two peaks of B3Z
activation were observed, one present in the void fraction
(Mr >800,000) and the other coinciding with the elution of two major proteins of apparent molecular weights of 550,000 (Fig. 4A). The void fraction from the gel filtration step contained both an aggregated protein fraction and a nucleic acid component, both of which elicited B3Z activation, and was not further
studied. As previously reported, native GRP94, because of its
relatively high frictional ratio, chromatographs on gel filtration
media with an apparent molecular weight of ~550,000 (24).
Immunoblot analysis of the gel filtration column fractions confirmed
that the three protein bands observed by Coomassie Blue staining (Fig.
4B) were GRP94, Hsp90, and calreticulin (Fig.
4C). In the depicted gel filtration profile, there was a
slight overlap in elution volumes between the GRP94/Hsp90 fraction and
calreticulin. Analysis of the calreticulin fraction in the B3Z
activation assay indicated that it was without activity (Fig.
4A). The data regarding calreticulin contrast with previous
data from our laboratory demonstrating that calreticulin derived from
full-length ovalbumin-producing cells (E.G7-OVA) displays OVA-specific
immunogenicity (3). Such differences may indicate that in
vivo calreticulin associates with a precursor OVA-bearing peptide
that is subsequently processed by antigen-presenting cells to yield the
minimal OVA epitope.
Having determined that the GRP94 and Hsp90 are primary immunogenic
components in a viral cell death model, related experiments were
performed to determine whether the GRP94 released into the extracellular space as a consequence of lethal vaccinia infection was
immunogenic. These series of studies were designed to address the most
physiologically relevant component of these studies, that being the
role of GRP94 as a cross-presentation antigen in scenarios of
pathological cell death (15, 16, 19). Thus, although the data in Fig. 4
indicate that GRP94 purified from virus-infected cells is immunogenic,
it was necessary to determine whether GRP94 can perform a pathological
cell death messenger function in transferring immunogenic peptides from
dying cells to the major histocompatibility complex class I antigen
presentation pathway of antigen-presenting cells. To address this
question, P815 mastocytoma cell cultures were subjected to lethal viral infection with rVV ES-OVAMet258-265 and centrifuged, and the supernatant (extracellular) fraction was recovered. This fraction was then concentrated and fractionated by gel filtration chromatography on Sephacryl S-300 resin (Fig. 5).
Consistent with results obtained in analyses of the cell-derived
chaperone fraction, the peak of B3Z activation coincided with the peak
GRP94-containing fractions (Fig. 5A), as determined by
immunoblot analysis (Fig. 5B).
The fractions obtained by gel filtration chromatography of the
concentrated tissue culture supernatant contained a complex, diverse
array of proteins, reflecting both serum components and those cellular
proteins released in response to pathological cell death (data not
shown). To address the relative contribution of GRP94 to the total
OVA-specific immunogenic activity of the peak activity fractions, a
GRP94 immunodepletion experiment was performed. As depicted in Fig.
5C, immunoaffinity depletion of GRP94 from a peak activity
fraction yielded a 60% decrease in OVA-specific activity. Under the
described immunoaffinity depletion conditions, GRP94 was efficiently
removed from the indicated fraction (Fig. 5C,
inset). On the basis of the data presented in Fig. 4, it is likely that the remaining OVA-specific activity is derived from cytosolic Hsp90. In summary, these data identify GRP94 as a prominent, soluble immunogenic component released from cells in response to
pathological cell death.
As a consequence of pathological cell death, which accompanies
lethal infection with vaccinia virus, GRP94 is released into the
extracellular space and can function as a cross-presentation antigen in
the MHC class I pathway. These observations extend recent findings
demonstrating the release of GRP94 (gp96) in cells subjected to
mechanical cell death (freeze/thaw) (19) and identify a physiologically
relevant role for GRP94 in the regulation of immune responses to
pathological cell death.
The mechanism of vaccinia-elicited cell death is, as yet, undefined. In
a manner similar to a number of viruses, including Epstein-Barr,
adenovirus, and human papilloma virus, infection with vaccinia results
in the expression of virally encoded anti-apoptotic signals that block
the progression to apoptotic cell death, indicating that lethal
vaccinia infection elicits cell death by a nonapoptotic mechanism (30).
In contrast, however, vaccinia infection of immature dendritic cells
and immature B-lymphocytes has been reported to elicit apoptotic cell
death (31, 32). Etoposide-induced apoptotic cell death results in the
calpain-mediated proteolysis of GRP94 (28). That GRP94 was recovered in
the tissue culture supernatant fraction in a structurally intact form
following vaccinia infection (Fig. 1) supports the conclusion that
terminal infection with vaccinia elicits nonapoptotic cell death.
Most significantly, and regardless of the precise molecular mechanism
by which terminal vaccinia infection elicits cell mortality, the end
stage of a lethal vaccinia infection is accompanied by a loss of both
plasma and ER membrane integrity and the release of cellular
components, including ER chaperones, into the extracellular space.
Matzinger (15), in the danger hypothesis, has proposed that
necrotic, but not apoptotic, cell death yields the production of
inflammatory signals necessary for the activation of cellular immune
responses. In support of this hypothesis, recent studies have
demonstrated that lysed cell extracts contain components capable of
eliciting dendritic cell activation and maturation (16-19). There
exists substantial experimental evidence indicating that heat shock and
chaperone proteins can themselves perform such functions. For example,
Hsp70 has been demonstrated to elicit cytokine release as well as to
direct peptide antigens into the MHC class I antigen presentation
pathway (17, 20, 26, 33). Similarly, GRP94 can function as an MHC class
I cross-presentation antigen, and recent data convincingly demonstrate
that GRP94 induces cytokine expression in both macrophages and
dendritic cells (3, 5, 8, 11, 19). Interestingly, the profile of
cytokines secreted in response to GRP94 is distinct from those released following addition of bacterial lipopolysaccharide (19). Given that
Hsp70 and GRP94 appear to fulfill the requirements predicted of
a cell death messenger, it becomes important to identify the physiological scenarios in which pathological cell death contributes to
heat shock or chaperone protein release. In addition to lethal viral
infection, as illustrated herein, it would be of value to determine
whether chaperones and heat shock proteins are released into the
extracellular space during chronic inflammation, particularly as
accompanies the onset of autoimmune disease (34, 35).
Previously, we and others reported that the ER chaperone, calreticulin,
can elicit epitope- and tumor-specific CD8+ T cell
responses (3, 36). Of relevance to the current study, calreticulin from
an ovalbumin-expressing cell line, E.G7-OVA, was reported to elicit an
OVA-specific cytotoxic T lymphocyte response (3). As is evident from
Fig. 4, however, the calreticulin fraction obtained from cells infected
with a recombinant vaccinia virus expressing an OVA minigene did not
display activity in an OVA re-presentation assay. If it is assumed that
the uptake and processing of calreticulin from virus-infected cells are
identical to that occurring with calreticulin from normal and tumor
tissue, it would appear, then, that calreticulin is unable to bind the minimum OVA epitope in a stable manner. At present, the sequence and
size determinants for peptide binding to calreticulin are not known,
although the ability of calreticulin to function as a lectin is
well established (37, 38). Asn-292 of ovalbumin is subject to
N-linked glycosylation, and so the possibility exists that
calreticulin binds an OVA precursor peptide that extends through the
OVA epitope (amino acids 257-264) and includes Asn-292, the site of
N-linked glycosylation.
It remains to be determined whether in vivo pathological
cell death yields the release of GRP94 into the extracellular space. The data included herein identify a potential role for GRP94 in the
regulation of immune response to pathological cell death. In addition,
the experimental system used in the present studies is well suited to
the analysis of the immunogenic and regulatory components produced
and/or released by cells undergoing pathological cell death.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-D-galactopyranoside (Sigma)
substrate as described previously (25). The linear range of OVA
re-presentation sensitivity was determined by the addition of serial
dilutions of SIINFEKL to the medium.
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (22K):
[in a new window]
Fig. 1.
Endoplasmic chaperones release in different
cell death scenarios. 1 × 106 E.G7-OVA cells in
1 ml of tissue culture medium were subjected to either 0.005%
digitonin treatment (lane 3), the addition of 5 µM ionomycin (lane 4), or freeze/thaw
treatment (lane 5). For lane 6, P815 cells were
infected with a recombinant vaccinia virus encoding the modified OVA
epitope MIINFEKL, in a signal sequence-bearing minigene construct, at a
multiplicity of infection of 5 for 1 h. Cultures were maintained
for 48 h at 37 °C and processed as described below. Lane
1 contains a purified GRP94 standard; lanes 2 and
7 represent the paired, no addition control conditions.
Following treatment, cell suspensions were centrifuged (15 min, 50,000 rpm, Beckman TL100.2 rotor), and the resulting supernatant was retained
as the soluble fraction. Supernatant extracts were fractionated with
40% (w/v) ammonium sulfate; the glycoprotein fraction in the 40%
ammonium sulfate supernatant was purified by adsorption onto
concanavalin A-Sepharose beads and eluted with SDS-PAGE sample buffer.
Depicted is a montage digital image of an immunoblot for GRP94.
View larger version (41K):
[in a new window]
Fig. 2.
Biochemical fractionation of
freeze/thaw-derived cell extracts. A, fractionation of
purified GRP94 and ovalbumin by centrifugal ultrafiltration. A solution
of purified GRP94 and ovalbumin was subjected to two cycles of
centrifugal ultrafiltration on a Microcon100 ultrafiltration device.
Filtrate and retentate fractions were concentrated by acid
precipitation, resolved by SDS-PAGE, and identified by Coomassie Blue
staining. B, ultrafiltration-based size exclusion
fractionation of GRP94 in freeze/thaw-derived cell extracts. E.G7-OVA
cells were killed by freeze/thaw treatment, centrifuged to remove the
insoluble fraction, and fractionated as described above. A Coomassie
Blue-stained gel and immunoblot analysis of the fractions is presented.
C, linearity of OVA re-presentation assay. -Galactosidase
(LacZ) activity produced by reporter B3Z T cells following stimulation
by RAW309 Cr.1 macrophages pulsed with increasing concentrations of OVA
peptide (SIINFEKL). D, GRP94 is the primary OVA-bearing
immunogenic component of the high molecular weight fraction of
freeze/thaw-derived lysates. RAW309 macrophage cultures were pulsed
with the ultrafiltration retentate of a freeze/thaw-treated lysate
derived from E.G7-OVA cultures, and re-presentation was assayed as B3Z
cell activation. 100 nM ovalbumin was used as a positive
control; LacZ produced by co-culture of RAW309 and B3Z cells alone was
subtracted from all readings as background. The GRP94 component of the
retentate was depleted by batch adsorption to an affinity-purified
anti-GRP94 IgG matrix. Error bars are S.D. of four independently
generated killed cell supernatants.
View larger version (27K):
[in a new window]
Fig. 3.
GRP94 is released following secondary
necrosis but not apoptosis. EL4 cells were cultured in serum-free
medium for the indicated time periods, and the supernatant
fraction was collected following centrifugation and processed for GRP94
immunoblot, as described in the legend to Fig. 1 (A), cell
culture viability was assayed by trypan blue vital dye staining
(B), or the cells were collected and assayed for the
induction of apoptosis by staining with fluorescein isothiocyanate
(FITC)-labeled annexin V and fluorescence-activated cell
sorting (C).
View larger version (38K):
[in a new window]
Fig. 4.
GRP94 and Hsp90 are dominant OVA-specific
immunogenic components of cells infected with OVA-expressing
recombinant vaccinia virus. 1 × 108 P815 cells
were infected with rVV ES-OVAMet258-265 at a
multiplicity of infection of 5 for 48 h. The cell pellet was
extracted in detergent, and the supernatant was subjected to MonoQ
chromatography. GRP94-containing fractions were pooled and separated on
a Sephacryl S300 column. Results from the S300 fractionation are shown.
A, protein elution profile (solid line) and the
paired B3Z activity profile (filled circles) are presented.
Aliquots of the indicated column fractions were incubated overnight
with 106 B3Z cells and 3 × 105 RAW309
cells. -Galactosidase activity was assayed as described under
"Materials and Methods." B, Coomassie Blue profile of
S300 gel filtration chromatography fractions. Aliquots of the column
fractions were subjected to SDS-PAGE, and the gel was stained with
Coomassie Blue. A digital image of the Coomassie Blue stained gel is
depicted. C, immunoblot analysis of GRP94, Hsp90, and
calreticulin (CRT) elution from a Sephacryl S300 gel
filtration column. The indicated fractions were separated by
SDS-PAGE, transferred to nitrocellulose membranes, and screened for
GRP94, Hsp90, and calreticulin content using antibodies specific for
the indicated proteins.
View larger version (16K):
[in a new window]
Fig. 5.
Immunogenic GRP94 is released into the
extracellular space following lethal viral infection. 1 × 108 P815 cells were infected with rVV
ES-OVAMet258-265 at a multiplicity of infection of 5 for
48 h. The tissue culture supernatant fraction was collected,
cleared of cells and cell debris by centrifugation, and concentrated
with a 30-kDa molecular mass cutoff centrifugal ultrafiltration
unit. A, the concentrated tissue culture supernatant was
subsequently size-fractionated on a Sephacryl S300 gel filtration
column in phosphate-buffered saline. Samples were assayed for B3Z
stimulatory activity as described under "Materials and Methods" and
summarized in the legend to Fig. 4. B, in parallel,
fractions were resolved on SDS-PAGE and screened for the presence of
GRP94 by immunoblot analysis with chemiluminescent detection. A digital
image of the developed immunoblot is depicted. C, GRP94
immunodepletion. A peak fraction sample was depleted of GRP94 by
immunoaffinity batch adsorption and subsequently assayed for
re-presentation activity in the B3Z assay system described above. The
efficiency of the immunoaffinity depletion is depicted in C,
inset.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. N. Shastri, Dr. S. Nair, and Dr. D. Boczkowski for reagents, the Duke University Comprehensive Cancer Center shared confocal microscopy resource (with help from H. Soleri and J. Gross), and the Duke University Comprehensive Cancer Center FACS facility. Helpful discussions and suggestions were received from Dr. J. J. Wassenberg and M. F. N. Rosser.
![]() |
FOOTNOTES |
---|
* These studies were supported by National Institutes of Health Grant DK53058 (to C. V. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
A Harry Hutchison Gibson Fellow in Cancer.
§ To whom correspondence should be addressed. Tel.: 919-684-8948; Fax: 919-684-5481; E-mail: c.nicchitta@cellbio.duke.edu.
Published, JBC Papers in Press, March 28, 2001, DOI 10.1074/jbc.M101836200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: ER, endoplasmic reticulum; APC, antigen-presenting cell; MHC, major histocompatibility complex; OVA, ovalbumin; PAGE, polyacrylamide gel electrophoresis; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Tamura, Y.,
Peng, P.,
Liu, K.,
Daou, M.,
and Srivastava, P. K.
(1997)
Science
278,
117-120 |
2. | Udono, H., Levey, D. L., and Srivastava, P. K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3077-3081[Abstract] |
3. |
Nair, S.,
Wearsch, P. A.,
Mitchell, D. A.,
Wassenberg, J. J.,
Gilboa, E.,
and Nicchitta, C. V.
(1999)
J. Immunol.
162,
6426-6432 |
4. | Arnold, D., Faath, S., Rammensee, H., and Schild, H. (1995) J. Exp. Med. 182, 885-889[Abstract] |
5. | Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. (1998) Immunity 8, 657-665[Medline] [Order article via Infotrieve] |
6. | Nicchitta, C. V. (1998) Curr. Opin. Immunol. 10, 103-109[CrossRef][Medline] [Order article via Infotrieve] |
7. | Heemels, M.-T., and Ploegh, H. (1995) Annu. Rev. Biochem. 64, 463-491[CrossRef][Medline] [Order article via Infotrieve] |
8. |
Singh-Jasuja, H.,
Toes, R. E.,
Spee, P.,
Munz, C.,
Hilf, N.,
Schoenberger, S. P.,
Ricciardi-Castagnoli, P.,
Neefjes, J.,
Rammensee, H. G.,
Arnold-Schild, D.,
and Schild, H.
(2000)
J. Exp. Med.
191,
1965-1974 |
9. |
Wassenberg, J. J.,
Dezfulian, C.,
and Nicchitta, C. V.
(1999)
J. Cell Sci.
112,
2167-2175 |
10. | Binder, R. J., Han, D. K., and Srivastava, P. K. (2000) Nat. Immunol. 2, 151-155[CrossRef] |
11. | Suto, R., and Srivastava, P. K. (1995) Science 269, 1585-1588[Medline] [Order article via Infotrieve] |
12. | Trump, B. F., Berezesky, I. K., Chang, S. H., and Phelps, P. C. (1997) Toxicol. Pathol. 25, 82-88[Medline] [Order article via Infotrieve] |
13. | Melcher, A., Gough, M., Todryk, S., and Vile, R. (1999) J. Mol. Med. 77, 824-833[CrossRef][Medline] [Order article via Infotrieve] |
14. | Duvall, E., and Wyllie, A. H. (1986) Immunol. Today 7, 115-119 |
15. | Matzinger, P. (1994) Annu. Rev. Immunol. 12, 991-1045[CrossRef][Medline] [Order article via Infotrieve] |
16. | Gallucci, S., Lolkema, M., and Matzinger, P. (1999) Nat. Med. 5, 1249-1255[CrossRef][Medline] [Order article via Infotrieve] |
17. |
Todryk, S.,
Melcher, A. A.,
Hardwick, N.,
Linardakis, E.,
Bateman, A.,
Colombo, M. P.,
Stoppacciaro, A.,
and Vile, R. G.
(1999)
J. Immunol.
163,
1398-1408 |
18. |
Sauter, B.,
Albert, M. L.,
Francisco, L.,
Larsson, M.,
Somersan, S.,
and Bhardwaj, N.
(2000)
J. Exp. Med.
191,
423-434 |
19. |
Basu, S.,
Binder, R. J.,
Suto, R.,
Anderson, K. M.,
and Srivastava, P. K.
(2000)
Int. Immunol.
12,
1539-1546 |
20. | Asea, A., Kreaft, S.-K., Kurt-Jones, E., Stevenson, M. A., Chen, L. B., Finberg, R. W., Koo, G. C., and Calderwood, S. K. (2000) Nat. Med. 4, 435-442[CrossRef] |
21. | Moore, M. W., Carbone, F. R., and Bevan, M. J. (1988) Cell 54, 777-785[Medline] [Order article via Infotrieve] |
22. | Karttunen, J., Sanderson, S., and Shastri, N. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6020-6024[Abstract] |
23. |
Restifo, N. P.,
Bacik, I.,
Irvine, K. R.,
Yewdell, J. W.,
McCabe, B. J.,
Anderson, R. W.,
Eisenlohr, L. C.,
Rosenberg, S. A.,
and Bennink, J. R.
(1995)
J. Immunol.
154,
4414-4422 |
24. | Wearsch, P. A., and Nicchitta, C. V. (1996) Protein Expression Purif. 7, 114-121[CrossRef][Medline] [Order article via Infotrieve] |
25. |
Shastri, N.,
and Gonzalez, F.
(1993)
J. Immunol.
150,
2724-2736 |
26. |
Moroi, Y.,
Mayhew, M.,
Trcka, J.,
Hoe, M. H.,
Takechi, Y.,
Hartl, F. U.,
Rothman, J. E.,
and Houghton, A. N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3485-3490 |
27. | McConkey, D. J. (1998) Toxicol. Lett. 99, 157-168[CrossRef][Medline] [Order article via Infotrieve] |
28. |
Reddy, R. K.,
Lu, J.,
and Lee, A. S.
(1999)
J. Biol. Chem.
274,
28476-28483 |
29. |
Leist, M.,
Single, B.,
Castoldi, A. F.,
Kuhnle, S.,
and Nicotera, P.
(1997)
J. Exp. Med.
185,
1481-1486 |
30. | Gillet, G., and Brun, G. (1996) Trends Microbiol. 4, 312-317[CrossRef][Medline] [Order article via Infotrieve] |
31. |
Engelmayer, J.,
Larsson, M.,
Subklewe, M.,
Chahroudi, A.,
Cox, W. I.,
Steinman, R. M.,
and Bhardwaj, N.
(1999)
J. Immunol.
163,
6762-6768 |
32. | Baixeras, E., Cebrian, A., Albar, J. P., Salas, J., Martinez, A. C., Vinuela, E., and Revilla, Y. (1998) Virus Res. 58, 107-113[CrossRef][Medline] [Order article via Infotrieve] |
33. |
Udono, H.,
and Srivastava, P. K.
(1994)
J. Immunol.
152,
5398-5403 |
34. | Steinhoff, U., Brinkmann, V., Klemm, U., Aichele, P., Seiler, P., Brandt, U., Bland, P. W., Prinz, I., Zugel, U., and Kaufmann, S. H. (1999) Immunity 11, 349-358[Medline] [Order article via Infotrieve] |
35. | Rodenburg, R. J., Raats, J. M., Pruijn, G. J., and van Venrooij, W. J. (2000) Bioessays 22, 627-636[CrossRef][Medline] [Order article via Infotrieve] |
36. |
Basu, S.,
and Srivastava, P. K.
(1999)
J. Exp. Med.
189,
797-802 |
37. | Vassilakos, A., Michalak, M., Lehrman, M. A., and Williams, D. B. (1998) Biochemistry 37, 3480-3490[CrossRef][Medline] [Order article via Infotrieve] |
38. |
Spiro, R. G.,
Zhu, Q.,
Bhoyroo, V.,
and Soling, H. D.
(1996)
J. Biol. Chem.
271,
11588-11594 |